GHRP-6

Evidence Limitation Notice: The safety profile of GHRP-6 is based on limited preclinical evidence only. No human clinical trials were identified in the current evidence base, which significantly limits our understanding of safety in humans.

Known Side Effects

The available evidence does not provide specific information about side effects in humans or clinical populations. All studies identified were conducted in animal models (rats, mice, fish, and chickens), making it impossible to determine human-relevant adverse effects from this evidence base.

Contraindications

No specific contraindications for GHRP-6 use have been established in the available evidence. However, given the lack of human safety data, the compound should be considered investigational.

Drug Interactions

The evidence does not provide information about potential drug interactions with GHRP-6. One study examined interactions with cannabinoid and ghrelin systems in animal models, but this does not establish clinically relevant drug interaction profiles for human use.

Populations That Should Avoid Use

Due to the absence of human safety data:

• Pregnant and breastfeeding women should avoid use, as safety during pregnancy and lactation has not been established
• Children and adolescents should avoid use due to lack of pediatric safety data
• Individuals with existing medical conditions should exercise extreme caution, as interactions with disease states are unknown

Special Considerations

The evidence indicates GHRP-6 affects growth hormone pathways and has been studied in models of cardiac injury, lung injury, and kidney injury. However, these preclinical findings cannot be extrapolated to determine safety in healthy humans or specific patient populations.

Medical Disclaimer: This information is for educational purposes only and should not be used for medical decision-making. The lack of human clinical trial data makes GHRP-6's safety profile largely unknown. Consult with a healthcare provider before considering any use of this investigational compound.

Evidence Quality Assessment

The safety evidence for GHRP-6 is extremely thin, consisting entirely of preclinical animal studies. No human trials, case reports, or clinical safety data were identified in the current evidence base.